肾下腹主动脉瘤腔内修复术后Ⅱ型内漏的结局:血管质量倡议-医保数据关联分析
基于血管质量倡议-医保数据库2010至2018年择期EVAR患者回顾性分析,纳入8195例,其中T2EL组1542例(19%)。T2EL组5年动脉瘤相关再干预率显著更高(30.4% vs 11%;P<.0001),但破裂豁免率与总生存率无显著差异,再干预与生存无关。
要点
- T2EL发生于约19%的EVAR术后患者,5年动脉瘤相关再干预率显著高于无T2EL组(30.4% vs 11%)。
- T2EL组与无T2EL组5年破裂豁免率无显著差异(95.6% vs 98.2%,aHR 0.98,95%CI 0.5-2.0)。
- T2EL患者中再干预与5年总生存无显著关联(aHR 0.45,95%CI 0.1-1.9,P=.27)。
核心结论
- T2EL发生于近五分之一的EVAR术后患者,与更高的再干预率相关,但再干预并未带来生存获益,孤立性T2EL再干预的总体获益尚待明确。
研究设计与样本
- 回顾性队列研究,使用血管质量倡议-医保(Vascular Quality Initiative-Medicare)数据库2010至2018年所有择期EVAR病例,最终纳入8195例,T2EL组1542例(19%),无T2EL组6653例(81%)。
主要发现
- T2EL组患者年龄更大(76岁 vs 75岁;P=.006),当前吸烟率更低(21% vs 26%;P<.001),慢性阻塞性肺疾病(28% vs 32%;P=.003)、充血性心力衰竭(9% vs 12%;P=.004)及既往血管干预史比例更低。
- 5年动脉瘤相关再干预率T2EL组显著高于无T2EL组(30.4% vs 11%;P<.0001)。
- 5年破裂豁免率两组无显著差异(95.6% vs 98.2%,aHR 0.98,95%CI 0.5-2.0)。
- 5年未调整总生存率两组相似(74% vs 71%);多因素回归中T2EL与死亡风险增加无关(aHR 0.83;95%CI 0.69-1.01;P=.057)。
- T2EL患者亚组分析中,再干预与5年总生存无显著关联(aHR 0.45;95%CI 0.1-1.9;P=.27)。
临床怎么用
- 原文结论指出,孤立性T2EL再干预的总体获益在当前实践中尚待明确,未据此给出具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Type II endoleaks (T2ELs) are commonly identified after endovascular aneurysm repair (EVAR) and may occur either at the completion of the procedure or during follow-up. However, the impact of T2EL on reintervention and survival remains poorly described. This study aims to evaluate the outcomes associated with T2EL in a real-world cohort using the Vascular Quality Initiative linked Medicare claims (Vascular Quality Initiative-Medicare) database. METHODS: We retrospectively reviewed all elective EVARs in the Vascular Quality Initiative-Medicare (part of the Vascular Implant Surveillance and Interventional Outcomes coordinated registry network) database from 2010 to 2018. Patients with Medicare fee-for-service entitlement at the time of the index procedure and continuous entitlement during follow-up were included. We excluded patients with endoleaks other than T2EL at completion or follow-up, those with missing T2EL status at completion, and patients with no imaging follow-up. The primary outcomes were aneurysm-related reintervention, freedom from rupture, and overall survival. A time-dependent analysis based on the T2EL status and Cox proportional hazards multivariable models were used to assess associations between T2EL and the outcomes. RESULTS: A total of 8195 patients were included in the final analysis, with 6653 (81%) in the no T2EL group and 1542 (19%) in the T2EL group. Patients in the T2EL group were older (76 years vs 75 years; P = .006) and had lower rates of active smoking (21% vs 26%; P < .001), chronic obstructive pulmonary disease (28% vs 32%; P = .003), congestive heart failure (9% vs 12%; P = .004), and a history of prior vascular intervention. At 5 years, the rate of aneurysm-related reintervention was significantly higher in the T2EL group (30.4% vs 11%; P < .0001); however, there was no significant difference in freedom from rupture between the groups (95.6% vs 98.2%, adjusted hazard ratio [aHR], 0.98, 95% confidence interval [CI]. 0.5-2.0). Unadjusted overall survival rates at 5 years were similar between the groups (74% vs 71%). On multivariate regression analysis, the presence of a T2EL was not associated with an increased risk of mortality (aHR, 0.83; 95% CI, 0.69-1.01; P = .057). Subgroup analysis in patients with T2EL showed that reintervention was not significantly associated with overall survival at 5-years (aHR, 0.45; 95% CI, 0.1-1.9; P = .27). CONCLUSIONS: T2EL occurred in nearly one-fifth of patients after EVAR and was associated with a higher rate of reintervention compared with patients without T2EL. Yet, reinterventions were not linked to better survival. Thus, the overall benefit of reintervention for isolated T2EL in current practice remains to be defined.
引用
- Vaddavalli VV, Zheng X, Mao J, et al. Outcomes associated with type II endoleaks after infrarenal endovascular aneurysm repair in the Vascular Quality Initiative linked to Medicare claims. J Vasc Surg. 2025. PMID: 40339998. doi:10.1016/j.jvs.2025.04.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。